Tate And Lyle /£TATE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tate And Lyle
Tate & Lyle PLC is a global provider of ingredients and solutions to the food, beverage, and other industries. Founded in 1859, the company is headquartered in London, United Kingdom, and operates in the food processing sector. The company is publicly traded on the London Stock Exchange under the ticker symbol TATE.
- Ticker
- £TATE
- Sector
- Consumer Essentials
- Primary listing
- LSE
- Employees
- 4,840
- Headquarters
- London, United Kingdom
- Website
- www.tateandlyle.com
Tate And Lyle Metrics
BasicAdvanced
£2.5B
25.97
£0.22
0.35
£0.20
3.51%
Price and volume
Market cap
£2.5B
Beta
0.35
52-week high
£5.80
52-week low
£3.19
Average daily volume
1.3M
Dividend rate
£0.20
Financial strength
Current ratio
2.706
Quick ratio
1.499
Long term debt to equity
0.797
Total debt to equity
0.81
Dividend payout ratio (TTM)
90.72%
Interest coverage (TTM)
4.26%
Profitability
EBITDA (TTM)
392
Gross margin (TTM)
100.00%
Net profit margin (TTM)
4.84%
Operating margin (TTM)
12.11%
Effective tax rate (TTM)
25.19%
Revenue per employee (TTM)
£410,000
Management effectiveness
Return on assets (TTM)
4.11%
Return on equity (TTM)
6.15%
Valuation
Price to earnings (TTM)
25.968
Price to revenue (TTM)
1.242
Price to book
1.56
Price to tangible book (TTM)
3.04
Price to free cash flow (TTM)
23.737
Free cash flow yield (TTM)
4.21%
Free cash flow per share (TTM)
0.237
Dividend yield (TTM)
3.51%
Growth
Revenue change (TTM)
15.55%
Earnings per share change (TTM)
-37.06%
3-year revenue growth (CAGR)
4.64%
10-year revenue growth (CAGR)
-1.59%
3-year earnings per share growth (CAGR)
-22.22%
10-year earnings per share growth (CAGR)
-6.09%
3-year dividend per share growth (CAGR)
2.29%
10-year dividend per share growth (CAGR)
-4.88%
What the Analysts think about Tate And Lyle
Analyst ratings (Buy, Hold, Sell) for Tate And Lyle stock.
Analyst projections of the future price of Tate And Lyle stock.
Bulls say / Bears say
Ingredion’s recommended all-cash offer gives shareholders a defined exit route, and Tate & Lyle investors approved the scheme in July. Completion still depends on regulatory and court conditions. (Tate & Lyle, Tate & Lyle)
There are signs of product-led growth: like-for-like revenue from new products rose 9% in FY26, the new-business pipeline grew 15%, and the cross-selling pipeline more than doubled in the second half. (Tate & Lyle)
Cost savings provide some support while sales recover: Tate & Lyle delivered $53m of productivity savings in FY26 and reached its $50m annualised CP Kelco cost-synergy target a year ahead of plan. (Tate & Lyle)
The takeover is not certain and may take time: material antitrust approvals and court sanction remain outstanding, with completion expected in the second half of 2027. The deal also brings together suppliers in overlapping ingredient markets, which could invite remedies or further scrutiny. (Tate & Lyle, The Grocer)
Trading remains soft: pro forma revenue and adjusted EBITDA each fell 3% in FY26. Management expects only modest revenue growth and broadly flat EBITDA in FY27, before the effect of the delayed bio-gums consolidation. (Tate & Lyle)
If the takeover fails, the standalone balance sheet leaves less room for error: net debt was £939m, leverage was 2.3 times EBITDA and cash conversion was 70%, below the 75% target. Adjusted earnings per share also fell 16% in FY26. (Tate & Lyle)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
Tate And Lyle Financial Performance
Revenues and expenses
Tate And Lyle Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Tate And Lyle
AllGBPUSDEUR
Fund name | Fund size | £TATE weighting |
|---|---|---|
Vanguard FTSE 250£VMIG | £569M | 0.66% |
Vanguard FTSE 250£VMID | £1.5B | 0.66% |
iShares FTSE 250£MIDD | £672M | 0.65% |
iShares UK Dividend£IUKD | £1.3B | 0.58% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.18% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.